Funding Disclosures in 2025

NRAS would like to thank the following companies for supporting the work of NRAS during 2025 and acknowledge financial payment of any consultancy work provided by NRAS to the work undertaken by industry partners.

Pharma Name	Project Name/Reason for Funding	Month	Amount	Beneficiary	Total 2025 Funding (ex VAT)
Alfasigma UK Limited	Corporate Membership	October	£12,600	NRAS
					£12,600
AnaptysBio Inc.	Corporate Membership	May	£12,600	NRAS
					£12,600
Biogen Idec Limited	Corporate Membership	November	£12,600	NRAS
					£12,600
Boehringer Ingelheim Limited	Real World Data Project (milestone 2)	November	£780	Boehringer Ingelheim
	Real World Data Project (milestone 3)	December	£780	Boehringer Ingelheim
					£1,560
Eli Lilly and Company Limited	Corporate Membership	January	£12,600	NRAS
	Reapproval and re-contracting of actors for ‘Behind the Smile’ video. Gift in kind only – value of work completed listed in ‘amount’.	N/A	£13,517	NRAS
					£12,600
Medac Pharma LLP	Corporate Membership	April	£12,600	NRAS
	Symptom Checker Funding	August	£7,500	NRAS
	Review of Patient Information Materials	November	£500	Medac
	Additional Symptom Checker Funding	December	£1,833.33	NRAS
					£22,433.33
UCB Pharma Ltd	Corporate Membership	February	£12,600
					£12,600

Total funding received from the pharmaceutical industry in 2025: £86,993.33